sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-[(2H7)propan-2-yl](5,7-2H2)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate

• ChemBase编号: 169308
• 分子式: C24H25FNNaO4
• 平均质量: 433.4477732
• 单一同位素质量: 433.16653079
• SMILES: c1cccc2c1c(c(n2C(C)C)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)c1ccc(cc1)F.[Na+]
• Canonical SMILES: [O-]C(=O)C[C@@H](C[C@@H](/C=C/c1c(c2ccc(cc2)F)c2c(n1C(C)C)cccc2)O)O.[Na+]
• InChI: InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m1./s1
• InChIKey: ZGGHKIMDNBDHJB-NRFPMOEYSA-M

名称和登记号

名称

• IUPAC标准名: sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-[(^2H₇)propan-2-yl](5,7-^2H₂)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate
• IUPAC传统名: sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-[(^2H₇)propan-2-yl](5,7-^2H₂)indol-2-yl]-3,5-dihydroxyhept-6-enoate
• 别名: (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl-deuterated)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; Fluindostatin-D8; XU 62-320-D8; Lescol-D8; Lipaxan-D8; Primexin-D8; Fluvastatin-D8 (Major) Sodium Salt

登记号

• CAS号: 1260178-87-7
• PubChem SID: 162263440
• PubChem CID: 71316903

理论计算性质

• Acid pKa: 4.55701
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 2.837187
• LogD (pH = 7.4): 1.0636245
• Log P: 3.8259492
• 摩尔折射率: 125.6924 cm^3
• 极化性: 46.024704 Å^3
• 极化表面积: 85.52 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Methanol; Water
• 外观: Yellow to Light Orange Solid
• 熔点: 194-197°C

安全信息

• 保存条件: -20°C Freezer, Under Inert Atmosphere

详细说明

Toronto Research Chemicals - F601252

A synthetic HMG-CoA reductase inhibitor. Antilipemic.A representative lot was: 1% of d6, 28% of d7, 37% of d8, 21% of d9, 10% of d10, and 2% of d11

参考文献

• Yuan, J., et al.: Atherosclerosis, 87, 147 (1991)
• Tse, F.L.S., et al.: J. Clin. Pharmacol., 32, 630 (1991)
• Dain, J.G., et al.: Drug Metab. Disposit., 21, 567 (1991)